scholarly journals A REVIEW OF TREATMENT, RISK FACTORS, AND INCIDENCE OF COLORECTAL CANCER

2022 ◽  
pp. 1-6
Author(s):  
FATIMA S. ALARYANI ◽  
SALMA SALEH TURKI ALRDAHE
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Monoclonal Antibodies ◽  
Developed Countries ◽  
Targeted Prevention ◽  
Treatment Risk ◽  
Geographical Variations ◽  
Time Courses ◽  
Major Factors ◽  
Growth And Aging

Colorectal cancer (CRC) is considered as the third most frequent cancer in the world and the incidence increases with increasing age. CRC accounts for nearly 9 % of all cancer incidence, with an estimated 1.4 million cases happening in 2012. The aim of this paper is to provide a review of incidence, risk factors, screening strategies, and treatment of colorectal cancer. We searched the studies in five English databases, including Web of Science, PubMed, Scopus, EMBASE, and Google Scholar with no limitation in publication time to find all papers regarding colorectal cancers. Papers with any language were included in the first step of search if they had an English abstract. We used the following words and terms including colorectal cancer, treatment, risk factor, diagnosis, chemotherapy, radiotherapy, surgery. Geographical variations and different time courses in the CRC incidence indicate that environmental factors and lifestyle are major factors in the development of this disease. The main preventable risk factors for CRC are nutrition, a high-fat diet, a low-fiber diet, obesity and physical inactivity, smoking and alcohol consumption, aspirin and nonsteroidal anti-inflammatory drugs, and some non-preventable risk factors such as age, gender, race, and diabetes mellitus. Colonoscopy remains the study of choice to diagnose colorectal cancer. Prior to any treatment, CT imaging of chest, abdomen and pelvis with contrast is needed for staging the patient’s CRC. The preferred option for localized colorectal cancer is surgery (etc, laparoscopic surgery, colostomy for rectal cancer); whereas the adjuvant chemotherapy is generally recommended for patients with lymph node metastases. Targeted treatment of colorectal cancer by monoclonal antibodies are important bioengineered proteins that can help the body's natural immune response to detect, attack, and kill cancer cells. Monoclonal antibodies may be used alone or in combination with other treatments such as chemotherapy. CRC accounts an important health problem worldwide that is estimated to increase because of the growth and aging of the population, and because of the adoption of at-risk manners and lifestyles, particularly in economically less developed countries. Screening has been confirmed to significantly decrease mortality and can prevent the onset of the disease. More international efforts are required to situate into practice targeted prevention approaches that might reduce the burden of CRC worldwide.

Patients’ Awareness Of The Prevention And Treatment Of Colorectal Cancer*

2015 ◽  
Vol 87 (9) ◽  
Author(s):  
Łukasz Dziki ◽  
Anna Puła ◽  
Konrad Stawiski ◽  
Barbara Mudza ◽  
Marcin Włodarczyk ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Treatment Process ◽  
Significant Negative Correlation ◽  
Study Group ◽  
Case Record ◽  
High Incidence ◽  
Prevention And Treatment ◽  
Major Factors ◽  
Medical University

Abstractwas to assess patients’ awareness of the prevention and treatment of colorectal cancer.Patients diagnosed with colorectal cancer, hospitalised at the Department of General and Colorectal Surgery of the Medical University in Łódź during the period from January 2015 to April 2015, were asked to complete a questionnaire concerning their families’ medical case record, factors predisposing them to the development of colorectal cancer, the tests applied in diagnostics, and the treatment process. The questionnaire comprised 42 closed-ended questions with one correct answer. A statistical analysis of all answers was carried out.The study group consisted of 30 men and 20 women aged 27–94 years old. A strong, statistically significant negative correlation between a patient’s age and his/her awareness of the prevention and treatment of colorectal cancer was noted (p<0.001; r= −0.51). The study demonstrated a statistically significant relationship between the occurrence of neoplasms in a patient’s family (p=0.009) or, more specifically, the occurrence of colorectal cancer (p=0.008), and the awareness of the prevention programme. The women’s group was characterised by statistically significantly greater awareness of colonoscopy as a screening examination (p=0.004).Patients need more information on colorectal cancer, its risk factors, prevention, the treatment process, and postoperative care. Lack of awareness of the colorectal cancer issue can be one of the major factors contributing to the high incidence of this disease.

scholarly journals Colorectal cancer in the Linxian China Nutrition Intervention Trial: Risk factors and intervention results

PLoS ONE ◽  
2021 ◽  
Vol 16 (9) ◽  
pp. e0255322
Author(s):  
Havva Keskin ◽  
Shao-Ming Wang ◽  
Arash Etemadi ◽  
Jin-Hu Fan ◽  
Sanford M. Dawsey ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Beta Carotene ◽  
Developed Countries ◽  
Dietary Factors ◽  
Fractional Factorial ◽  
Alpha Tocopherol ◽  
Nutrition Intervention ◽  
Intervention Trial ◽  
Incidence And Mortality

Background Colorectal cancer (CRC) is among the most common cancers in economically developed countries and developing world. While dietary factors are associated with risk of CRC in the West and urban China, little is known about risk or protective factors in rural China. Methods The Linxian General Population Nutrition Intervention Trial (NIT) cohort was established over 30 years ago to test whether daily multivitamin/mineral supplements could reduce the incidence and mortality of esophageal/gastric cardia cancer. The cohort included a total of 29,553 healthy participants 40–69 years old who were randomly assigned to supplements or placebos via a 24 fractional factorial study design. We examined risk factors for the development of CRC as well as the effects of four different nutritional factors (Factor A: retinol, zinc; B: riboflavin, niacin; C: ascorbic acid, molybdenum; D: selenium, alpha-tocopherol, beta-carotene,) on CRC incidence following 5.25 years of supplementation in this randomized, placebo-controlled intervention trial. Results CRC risk increased with age and height as well as piped water usage, family history of CRC, and consumption of foods cooked in oil, eggs, and fresh fruits. No effect on CRC was seen for any of these four intervention factors tested in both genders, but CRC was reduced 37% in females who received Factor D (selenium/alpha-tocopherol/beta-carotene) (RR = 0.63, 95% CI = 0.43–0.92, P = 0.016) compared to females who did not receive Factor D. Conclusions In this undernourished rural Chinese population, CRC risk factors in this Chinese cohort showed both similarities and differences compared to Western and urban Asian Chinese populations. Intervention results suggested a potential benefit for women supplemented with selenium/alpha-tocopherol/beta-carotene.

Colon cancer: risk factors and screening

2020 ◽  
pp. 13-22
Author(s):  
Mark Natanson
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Cancer Risk ◽  
Clinical Manifestations ◽  
Dysplastic Lesion ◽  
Test Analysis ◽  
Cancer Risk Factors ◽  
Colon Cancer Risk ◽  
Neoplastic Process ◽  
Rectal Cancers

Colon and rectal cancers are usually combined under the same term "colorectal cancer". It should be noted that the lesion of the colon is much more common. Colorectal cancer ranks fourth in the overall structure of oncological pathology in terms of prevalence, and in some countries even comes third after lung and stomach cancer. Risk factors that contribute to the development of colorectal cancer include bowel polyps, ulcerative colitis and Crohn's disease, and a genetic predisposition. Most often, neoplastic transformation occurs at the site of an adenoma or dysplastic lesion of the intestinal mucosa. Due to the high risk of neoplastic process in a sufficiently large number of elderly people, it is recommended that every person over the age of 50 should undergo compulsory screening to detect latent cancer. The simplest, but at the same time insufficiently informative method is a blood culture test - analysis for the presence of blood in the feces. Method of total colonoscopy and double-contrast radiography is distinguished by a higher information content, but at the same time a higher cost. It is recommended to have these examinations every three to five years after the age of 50 years without clinical manifestations, and after the age of 40 for those at risk for colorectal cancer.

A Critical Review of Second-generation anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer

2020 ◽  
Vol 21 ◽  
Author(s):  
Daniel Sur ◽  
Andrei Havasi ◽  
Alecsandra Gorzo ◽  
Claudia Burz
Keyword(s):  
Colorectal Cancer ◽  
Drug Resistance ◽  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Metastatic Colorectal Cancer ◽  
Second Generation ◽  
Current Data ◽  
Braf Mutations ◽  
Durable Response ◽  
Ongoing Research

Background: Anti-EGFR monoclonal antibodies (mAbs) have become a relevant solution for the treatment of patients with metastatic colorectal cancer. Current anti-EGFR monoclonal antibodies face a series of problems, including resistance and non-durable response, and RAS and BRAF mutations serve as exclusion criteria for treatment with anti-EGFR mAbs. Advances in molecular tumor profiling and information on subsequent pathways responsible for disease progression and drug resistance helped develop a new generation of anti-EGFR mAbs. These second-generation mAbs have been developed to overcome existing resistance mechanisms and to limit common side effects. For the moment, existing literature suggests that these novel anti-EGFR mAbs are far from finding their way to clinical practice soon. Objective: In this review, we summarize and evaluate current data regarding ongoing research and completed clinical trials for different second-generation anti-EGFR monoclonal antibodies. Conclusion: Anti-EGFR mAbs exhibit efficacy in advanced colorectal cancer, but second-generation mAbs failed to prove their benefit in the treatment of metastatic colorectal cancer. Understanding the biological basis of primary and acquired drug resistance could allow scientists to design better clinical trials and develop improved second-generation mAbs.

Free Fatty Acid Receptors as New Potential Targets in Colorectal Cancer

2020 ◽  
Vol 21 (14) ◽  
pp. 1397-1404
Author(s):  
Adrian Bartoszek ◽  
Jakub Fichna ◽  
Aleksandra Tarasiuk ◽  
Agata Binienda ◽  
Adam Fabisiak ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Fatty Acid ◽  
Free Fatty Acid ◽  
Current Knowledge ◽  
Developed Countries ◽  
Future Directions ◽  
Screening Programs ◽  
Pharmacological Targets ◽  
The Family ◽  
Free Fatty Acid Receptors

Colorectal cancer (CRC) is one of the most common cancers worldwide. In developed countries, its mortality remains high, yet the prevalence has established owing to effective screening programs; however due to the westernization of lifestyle, the incidences in many other countries have increased. Although the treatment of CRC has improved in the last few years, the side effects of these approaches cannot be neglected. Recently, members of the family of free fatty acid receptors (FFARs) have become attractive pharmacological targets in many diseases, including asthma; studies also point to their role in carcinogenesis. Here, we discuss current knowledge and future directions in FFAR research related to CRC. Contradictory results of FFARs modulation may derive from the pleiotropic effects of FFAR ligands, receptor distribution and different signal transduction. Hence, we indicate directions of further studies to fully use the potential of FFARs in CRC.

Sign in / Sign up

Export Citation Format

Share Document